Sign inJoin waitlistJoin the waitlist

Eric Mou

Hematology · State University of Iowa

Credentials: · · · · · ·

History

Research

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
Blood · 2021 · 122 citations
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium
Journal of Clinical Oncology · 2023 · 49 citations
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
Blood Advances · 2023 · 36 citations

BK
Brad Kahl
8 papers
Peter Martin
7 papers
Thomas Habermann
7 papers
Vincent Liu
7 papers
Yucai Wang
7 papers
Andrew Evens
6 papers
Andrew Feldman
6 papers
Izidore Lossos
6 papers
Jonathon Cohen
6 papers
Carla Casulo
5 papers
Christopher Flowers
5 papers
Jonathan Friedberg
5 papers

Clinical trials

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Site PI · Recruiting · Phase 1
Kyowa Kirin, Inc.
2026–2030
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Site PI · Recruiting · Phase 3
Eastern Cooperative Oncology Group
2025–2075
MB-105 in Patients With CD5 Positive T-cell Lymphoma
Site PI · Recruiting · Phase 2
March Biosciences Inc
2025–2029
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032